IBS Personalized Diet vs. Low FODMAP Diet Randomized Control Trial
Sponsor: Weizmann Institute of Science • ClinicalTrials.gov ID: NCT05972317
Recruiting for Similar Conditions?
Sponsors are looking for patients like you. See if you qualify for compensated research studies.
Check Eligibility →Description
Irritable bowel syndrome (IBS) is considered the most common gastrointestinal disorder in humans, with an estimated global prevalence of 11%-20% of all humans. Alterations in the gut microbiome are at the center of IBS, and microbiome-induced volatile metabolites in response to dietary exposures is believed to drive a downstream impact on susceptible hosts, thereby driving the disease. However, the characteristics and functions of these metabolites remain unknown to date. This placebo-controlled interventional study examines person-specific small molecules and bacteria driving IBS and their downstream effects on the human gut epithelium.
Interventions
-
Standard Low FODMAP dietary regimen
(Other)
Standard low FODMAP dietary regimen randomized re-introduction phase
-
personalized low FODMAP dietary regimen
(Other)
Low FODMAP dietary regimen with personalized re-introduction phase
Eligibility criteria
Conditions
Locations
- Weizmann institute of science — Rehovot, Israel
Partner with Nurenyx
Showcase your study to thousands of motivated patients matching your criteria.
Learn MoreOfficial Source
Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
View Official Record